RARE Daily

Medable Enters Partnership with Every Cure

January 5, 2023

Every Cure, the nonprofit working to repurpose approved therapies to treat rare diseases, has entered into a partnership with Medable to use its technology platform for patient-centered clinical trials.

Medable will partner with Every Cure by providing specialized software and services to conduct global, remote clinical trials for drug repurposing candidates. Medable’s software-as-a-service (SaaS) platform has been used in more than 300 decentralized and hybrid clinical trials, serving over one million patients and research participants in 60 countries.

“We live in an era of exponential improvements in medicine, but traditional clinical trials are a bottleneck in the system – and only yield 50 new FDA-approved treatments per year,” said Michelle Longmire, CEO and co-founder of Medable. “With new technologies and new research techniques, we believe it’s possible to drastically increase the number of therapies in development – and Every Cure will be an important leader in driving that change.”

Every Cure, co-founded by rare disease researcher and patient advocate David Fajgenbaum and backed by the Clinton Global Initiative, has developed a tool called the MATRIX that uses machine learning and AI to identify and rank promising treatments. A pilot study uncovered 106 promising drug repurposing opportunities in the first 147 diseases. In partnership with Medable, Every Cure will conduct clinical trials of the most promising and high impact opportunities for FDA-approval of an existing drug with a new indication.

“Patients around the world die every day from diseases that could have been cured by a drug sitting on the shelf at their local pharmacy,” said Fajgenbaum. “Every Cure is dedicated to unlocking all diseases that existing drugs can treat by developing a comprehensive open-source database of drug repurposing opportunities and launching clinical trials of the most promising treatments.”

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.